Full Text View
Tabular View
No Study Results Posted
Related Studies
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
This study is currently recruiting participants.
Verified May 2013 by Boehringer Ingelheim Pharmaceuticals
Study NCT01342484   Information provided by Boehringer Ingelheim Pharmaceuticals

First Received on April 26, 2011.   Last Updated on May 15, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes Mellitus, Type 2
Additional conditions recognized in this trial
Diabetes Mellitus
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
placebo
BI1356 low dose
BI1356 high dose
Additional drug interventions recognized in this trial
BI 1356
More general drug interventions related to this trial
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services